Zoetis Inc (NYSE:ZTS) insider Clinton A. Jr. Lewis sold 6,125 shares of the business’s stock in a transaction dated Monday, January 14th. The stock was sold at an average price of $85.21, for a total transaction of $521,911.25. Following the sale, the insider now owns 48,070 shares in the company, valued at $4,096,044.70. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Shares of ZTS traded down $1.60 during mid-day trading on Wednesday, hitting $83.21. The company’s stock had a trading volume of 3,880,583 shares, compared to its average volume of 2,471,399. The stock has a market capitalization of $40.60 billion, a P/E ratio of 34.67, a P/E/G ratio of 1.50 and a beta of 1.01. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. Zoetis Inc has a fifty-two week low of $70.20 and a fifty-two week high of $96.57.
Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.77 by $0.06. The company had revenue of $1.48 billion for the quarter, compared to analysts’ expectations of $1.46 billion. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The business’s revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 EPS. As a group, equities research analysts forecast that Zoetis Inc will post 3.11 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 18th will be paid a $0.164 dividend. The ex-dividend date is Thursday, January 17th. This represents a $0.66 annualized dividend and a dividend yield of 0.79%. This is a boost from Zoetis’s previous quarterly dividend of $0.13. Zoetis’s payout ratio is currently 20.83%.
Zoetis declared that its Board of Directors has initiated a stock buyback program on Wednesday, December 12th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the company to buy up to 4.7% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
A number of research firms have commented on ZTS. BMO Capital Markets restated a “hold” rating on shares of Zoetis in a research report on Sunday, November 11th. Argus set a $105.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research report on Tuesday, November 13th. JPMorgan Chase & Co. boosted their price target on shares of Zoetis from $100.00 to $101.00 and gave the stock an “overweight” rating in a research report on Friday, November 2nd. Cantor Fitzgerald restated an “overweight” rating and set a $105.00 price target (up from $98.00) on shares of Zoetis in a research report on Wednesday, October 17th. Finally, Zacks Investment Research upgraded shares of Zoetis from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Wednesday, October 17th. Seven equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Zoetis presently has an average rating of “Buy” and an average target price of $94.00.
Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. grew its stake in shares of Zoetis by 1.4% in the 3rd quarter. BlackRock Inc. now owns 37,653,394 shares of the company’s stock worth $3,447,546,000 after purchasing an additional 522,533 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Zoetis by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 35,947,496 shares of the company’s stock worth $3,291,353,000 after purchasing an additional 293,614 shares during the last quarter. Vanguard Group Inc grew its stake in shares of Zoetis by 0.8% in the 3rd quarter. Vanguard Group Inc now owns 35,947,496 shares of the company’s stock worth $3,291,353,000 after purchasing an additional 293,614 shares during the last quarter. Polen Capital Management LLC grew its stake in shares of Zoetis by 0.9% in the 3rd quarter. Polen Capital Management LLC now owns 9,374,674 shares of the company’s stock worth $858,345,000 after purchasing an additional 79,594 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Zoetis by 1.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 7,692,247 shares of the company’s stock worth $704,302,000 after acquiring an additional 119,154 shares in the last quarter. 89.86% of the stock is currently owned by institutional investors.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: How to invest in blue-chip stocks
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.